Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Preferred Regimens for Relapsed Myeloma

January 16th 2019

Transplant-Ineligible Myeloma: Daratumumab

January 16th 2019

Tailored Therapy for Elderly/Frail Patients With Myeloma

January 16th 2019

Role of Maintenance Therapy in Myeloma

January 16th 2019

Role of Consolidation Therapy in Myeloma

January 16th 2019

Newer Regimens in Myeloma: A Need for Transplant?

January 16th 2019

Assessing MRD Status in Myeloma

January 16th 2019

Quadruplet Therapy Prior to Transplant in Myeloma

January 16th 2019

Up-front Therapy With Carfilzomib in Myeloma

January 16th 2019

Treating Newly Diagnosed High-Risk Smoldering Myeloma

January 16th 2019

Identifying Between Smoldering and Active Myeloma

January 16th 2019

Dr. Cho on Targets for Immunotherapy in Multiple Myeloma

January 15th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses current and emerging targets for immunotherapy in the treatment of patients with multiple myeloma.

Dr. Martin on Selinexor in Penta-Refractory Patients With Myeloma

January 15th 2019

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

January 12th 2019

Peter Voorhees, MD, discusses the clinical potential of adding daratumumab to bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Dr. Voorhees Discusses Safety Run-in of Daratumumab in Myeloma

January 12th 2019

Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Pomalidomide Shows Benefit in Lenalidomide-Refractory Myeloma

January 11th 2019

David S. Siegel, MD, PhD, discusses a potentially practice-changing trial in multiple myeloma.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma

January 10th 2019

David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.

Dr. Madduri on the Standard of Care for Transplant Eligible Patients With Myeloma

January 8th 2019

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.